Document:

RETENTION AGREEMENT

 

This Retention Agreement (this “Agreement”)
is made and entered into as of May 16, 2014 (the “Effective Date”), by and between Senesco Technologies, Inc.,
a Delaware corporation (the “Company”) and Leslie J. Browne, Ph.D. (“Executive”).

 

WHEREAS, Executive has been serving
as the President and Chief Executive Officer of the Company and as a director of the Company, and as of the Effective Date, the
Executive has agreed to step down as a director and as the Chief Executive Officer of the Company, but he shall continue to serve
as the President of the Company;

 

WHEREAS, the Company has determined
that it is in the best interests of the Company to retain Executive;

 

WHEREAS, the Company and Executive
desire to enter into an agreement providing for the payment of severance benefits to Executive in the event of certain terminations
of Executive’s employment; and

 

WHEREAS, upon execution of this Agreement,
Executive will no longer be entitled to receive any payments or benefits under the Company’s Retention Policy for Officers
(or any other plan, policy or agreement providing for the payment of severance benefits) (the “Retention Policy”).

 

NOW, THEREFORE, in consideration
of the mutual covenants, promises and obligations set forth herein, the parties agree as follows:

 

1.           Severance
Triggering Events.

 

(a)          Upon
the occurrence of a Qualifying Termination (as defined in Section 8 below), Executive shall become eligible to receive the payments
and benefits set forth in Section 2, subject to the limitations set forth in this Agreement (including, without limitation, Section
5), in addition to any unpaid salary and benefits earned through the effective date of the Qualifying Termination.

 

(b)          Upon
the occurrence of a Change of Control Termination (as defined in Section 8 below), Executive shall become eligible to receive the
payments and benefits set forth in Section 3, subject to the limitations set forth in this Agreement (including, without limitation,
Section 5), in addition to any unpaid salary and benefits earned through the effective date of the Change of Control Termination.

 

For the avoidance of doubt, if Executive’s
termination of employment would constitute both a Qualifying Termination and a Change of Control Termination, Executive’s
termination shall be considered a Change of Control Termination entitling Executive to receive only the payments and benefits set
forth in Section 3.

 

    	 

    	 

    

 

2.           Severance
Benefits upon Qualifying Termination.

 

(a)          Cash
Severance. In the event of a Qualifying Termination, Executive will be entitled to a receive a lump sum cash payment, payable
in accordance with Section 4 and Section 9(f)(ii), in an amount equal to the sum of (i) Executive’s target bonus for
the calendar year in which his Qualifying Termination occurs, as determined by the Company’s Board of Directors (the “Board”),
plus (ii) one times Executive’s annual base salary, as in effect on the date of Executive’s Qualifying Termination.

 

(b)          Health
Benefits. Provided Executive and his eligible dependents elect to continue medical and dental care coverage under the Company’s
group health care plans pursuant to their rights under COBRA (or any similar state law) following Executive’s Qualifying
Termination and subject to Executive’s compliance with the reimbursement procedures set forth in Section 6, the Company shall
reimburse Executive for the costs Executive incurs to obtain such continued coverage for the twelve (12)-month period beginning
on the first day of the month following Executive’s Qualifying Termination. The number of months of continued benefit coverage
provided to Executive hereunder shall, to the maximum extent permitted by law, reduce the number of months of continued coverage
that must be made available to Executive and his dependents under COBRA (or any similar state law).

 

(c)          Life
Insurance. Provided Executive takes all action necessary to convert the life insurance benefit provided to Executive under
the Company’s group term life insurance policy to an individual policy and subject to Executive’s compliance with the
reimbursement procedures set forth in Section 6, the Company shall reimburse Executive for the costs Executive incurs to maintain
such individual policy (the “Life Insurance Costs”) during the twelve (12)-month period following Executive’s
Qualifying Termination. The Company shall have no obligation to provide any amount or benefit pursuant to this Section 2(c) if
for any reason the life insurance benefit provided to Executive under the Company’s group term life insurance policy is not,
or cannot be, converted to an individual policy.

 

(d)          Accelerated
Vesting. Notwithstanding anything to the contrary in the applicable award agreement, each of Executive’s then outstanding
equity awards shall become fully vested and exercisable (if applicable) as of the effective date of Executive’s Qualifying
Termination, and each of Executive’s options that remains outstanding following the effective date of the Qualifying Termination
shall remain exercisable until the expiration of its maximum option term.

 

3.           Severance
Benefits upon Change of Control Termination.

 

(a)          Cash
Severance. In the event of a Change of Control Termination, Executive will be entitled to a receive a lump sum cash payment,
payable in accordance with Section 4 and Section 9(f)(ii), in an amount equal to the sum of (i) Executive’s target
bonus for the calendar year in which his Change of Control Termination occurs, as determined by the Board, plus (ii) two times
Executive’s annual base salary, as in effect immediately prior to the closing of the Change of Control.

 

(b)          Health
Benefits. Provided Executive and his eligible dependents elect to continue medical and dental care coverage under the Company’s
group health care plans pursuant to their rights under COBRA (or any similar state law) following Executive’s Change of Control
Termination and subject to Executive’s compliance with the reimbursement procedures set forth in Section 6, the Company shall
reimburse Executive for the costs Executive incurs to obtain such continued coverage for the twenty-four (24)-month period beginning
on the first day of the month following the effective date of the Change of Control Termination. During the COBRA continuation
period, such coverage shall be obtained under the Company’s group health care plans. If applicable, following the completion
of the COBRA continuation period, such coverage shall continue under the Company’s group health plans or one or more other
plans or individual policies providing equivalent coverage. The number of months of continued benefit coverage provided to Executive
hereunder shall, to the maximum extent permitted by law, reduce the number of months of continued coverage that must be made available
to Executive and his dependents under COBRA (or any similar state law).

 

    	2

    	 

    

 

(c)          Accelerated
Vesting. Notwithstanding anything to the contrary in the applicable award agreement, each of Executive’s then outstanding
equity awards shall become fully vested and exercisable (if applicable) as of the effective date of Executive’s Change of
Control Termination, and each of Executive’s options that remains outstanding following the effective date of the Change
of Control Termination shall remain exercisable until the expiration of its maximum option term.

 

4.           Payment
Timing. Subject to Section 9(f)(ii), the Company shall make any lump sum cash payment that becomes payable to Executive under
Section 2(a) or Section 3(a) within the sixty (60)-day period measured from the date of Executive’s Qualifying Termination
or Change of Control Termination, as applicable, provided that the General Release (as defined in Section 5 below) has been delivered
by Executive pursuant to Section 5 below and is effective and enforceable following the expiration of the revocation period applicable
to that release under law. However, should such sixty (60)-day period span two taxable years, then such payment shall be made during
the portion of that sixty (60)-day period that occurs in the second taxable year.

 

5.           Release
Requirement. Notwithstanding anything herein to the contrary, in order to receive any severance payments or benefits pursuant
to this Agreement, Executive must first execute and deliver to the Company, within twenty-one (21) days (or forty-five (45) days,
if such longer period is required under applicable law) after the effective date of Executive’s Qualifying Termination or
Change of Control Termination, as applicable, a general settlement and release agreement in such form as provided by the Company
(a “General Release”), and such General Release must become effective and enforceable in accordance with its
terms following the expiration of any applicable revocation period under federal or state law. If such General Release is not executed
and delivered to the Company within the applicable twenty-one (21) (or forty-five (45))-day period hereunder or does not otherwise
become effective and enforceable in accordance with its terms, then no severance benefits will be provided to Executive under this
Agreement.

 

6.           Reimbursement
Procedure. In order to obtain reimbursement for the costs Executive incurs to obtain the continued medical and dental care
coverage provided for under Section 2 or Section 3 (collectively, the “Health Insurance Costs”) or the
Life Insurance Costs, Executive must submit appropriate evidence to the Company of each periodic payment within sixty (60) days
after the required payment date for those Health Insurance Costs or Life Insurance Costs, as applicable, and the Company shall
reimburse Executive for that payment within thirty (30) days after receipt of that submission. All such reimbursements shall be
subject to the provisions of Section 9(f)(iii).

 

7.           Limitation.
Notwithstanding the provisions of Section 3, if the aggregate amount of all payments and benefits to be provided to all officers
pursuant to the Retention Policy, plus the aggregate amount of all payments and benefits to be provided to Executive pursuant to
Section 3 exceeds ten percent (10%) of the value of the Change of Control transaction, as determined by the parties and reflected
in a definitive agreement, or if not reflected in a definitive agreement, then as determined by a qualified, independent third
party selected by the Board, the Board shall have the discretion to reduce the amount payable to Executive pursuant to Section
3 pro rata with any reduction made to the amounts payable to the Company’s officers pursuant to the Retention Policy, to
the extent the Board determines in its sole discretion that such a reduction is necessary in order for the Change of Control transaction
to be consummated.

 

    	3

    	 

    

 

8.           Definitions.
For purposes of this Agreement, the following definitions shall be in effect

 

(a)          Cause.
The term “Cause” shall mean any of the following:

 

(i)          Failure
by Executive, other than by reason of disability, to substantially perform duties consistent with those expected of a person holding
Executive’s position within twenty (20) business days following Executive’s receipt of written notice of such failure
(which notice shall have been authorized by the Board and shall set forth in reasonable detail the purported failure to perform
and the specific steps to cure such failure, which shall be consistent with the terms hereof);

 

(ii)         Executive’s
misappropriation of the Company’s funds or willful misconduct which results in material damage to the Company; or

 

(iii)        Executive’s
conviction of, or plea of nolo contendere to, any crime constituting a felony under the laws of the United States or any State
thereof, or any crime constituting a misdemeanor under any such law involving moral turpitude.

 

(b)          Change
of Control. The term “Change of Control” shall mean the occurrence of any of the following: (i) any “person”,
as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the “1934 Act”)
(other than (A) the Company or any subsidiary of the Company, (B) any trustee or other fiduciary holding securities under an employee
benefit plan of the Company or any subsidiary of the Company, or (C) any company owned, directly or indirectly, by the shareholders
of the Company in substantially the same proportions as their ownership of stock of the Company), becoming the “beneficial
owner” (as defined in Rule 13d-3 under the 1934 Act), directly or indirectly, in one or more related transactions, of securities
of the Company representing more than 50% of the combined voting power of the Company’s then outstanding securities; (ii)
a merger or consolidation approved by the Company’s stockholders (other than (A) a merger or consolidation which would result
in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding
or by being converted into voting securities of the surviving entity) 50% or more of the combined voting power of voting securities
of the Company or such surviving entity outstanding immediately after such merger or consolidation or (B) a merger or consolidation
effected to implement a recapitalization of the Company (or similar transaction) in which no person as such term is used in Sections
13(d) and 14(d) of the 1934 Act (other than the Company or subsidiary of the Company) acquires more than 50% of the combined voting
power of the Company’s then outstanding securities); (iii) the sale or other disposition of all or substantially all of the
Company’s assets; (iv) the issuance, in one or more related transactions, of securities of the Company representing more
than 50% of the combined voting power of the Company’s then outstanding securities, in which any “person” (as
such term is used in Sections 13(d) and 14(d) of the 1934 Act) becomes a beneficial owner (as defined in Rule 13d-3 under the 1934
Act) of at least 20% of the combined voting power of the Company’s then outstanding securities, or (v) a change in the composition
of the Board over a period of twelve (12) consecutive months or less such that a majority of the Board members ceases, by reason
of one or more contested elections for Board membership, to be comprised of individuals who either (a) have been Board members
continuously since the beginning of such period or (b) have been elected or nominated for election as Board members during such
period by at least a majority of the Board members described in clause (a) who were still in office at the time the Board approved
such election or nomination.

 

    	4

    	 

    

 

(c)          Good
Reason. The term “Good Reason” shall mean any action by the Company which results in:

 

(i)          A
material diminution of Executive’s position or Executive’s authority, duties or responsibilities;

 

(ii)         A
material reduction in Executive’s annual base salary; or

 

(iii)        A
change by the Company in the location at which Executive performs his principal duties for the Company to a new location that is
outside a radius of 50 miles from Executive’s principal residence and outside a radius of 50 miles from the location at which
Executive previously performed his principal duties for the Company;

 

provided, that, the foregoing events
shall not be deemed to constitute Good Reason unless Executive shall have notified the Board in writing of the occurrence of such
event(s) within ninety (90) days of the initial existence of the condition and the Board shall have failed to have cured or remedied
such event(s) within thirty (30) days of its receipt of such written notice or which breach the Company shall have failed to begin
to attempt to cure during said thirty (30)-day period if the breach is not curable during the thirty (30)-day period. If the event
is not cured during the thirty (30)-day period (or the Company shall have failed to begin to attempt to cure the event during such
thirty (30)-day period), Executive’s employment shall terminate on the ninetieth (90th) day following the date of Executive’s
notice to the Board of the event constituting Good Reason, unless the Board and Executive agree in writing to an extension of Executive’s
termination date.

 

(d)          Qualifying
Termination. The term “Qualifying Termination” shall mean any of the following:

 

(i)          The
Company terminates Executive’s employment without Cause during the twelve (12)-month period commencing with the Effective
Date;

 

(ii)         Executive
voluntarily terminates his employment with the Company for Good Reason (following the applicable notice and cure period requirements
specified in Section 8(c)), which termination becomes effective during the twelve (12)-month period commencing with the Effective
Date; or

 

(iii)        Executive
is not offered the position of “Chief Executive Officer” of the Company on or before the first anniversary of the Effective
Date and Executive voluntarily resigns from employment with the Company during the thirty (30)-day period commencing with the first
anniversary of the Effective Date.

 

    	5

    	 

    

 

(e)          Change
of Control Termination. The term “Change of Control Termination” shall mean any of the following:

 

(i)          The
Company terminates Executive’s employment without Cause upon, immediately prior to, or within 180 days after, the effective
date of a Change of Control; or

 

(ii)         Executive
voluntarily terminates his employment with the Company for Good Reason (following the applicable notice and cure period requirements
specified in Section 8(c)) upon, immediately prior to, or within 180 days after, the effective date of a Change of Control.

 

9.           Miscellaneous
Provisions.

 

(a)          Notice.
Notices and all other communications contemplated by this Agreement shall be in writing and shall be deemed to have been duly given
when personally delivered or when mailed by U.S. registered or certified mail, return receipt requested and postage prepaid. In
the case of Executive, mailed notices shall be addressed to him at the home address which he most recently communicated to the
Company in writing. In the case of the Company, mailed notices shall be addressed to its corporate headquarters, and all notices
shall be directed to the attention of its Secretary.

 

(b)          Entire
Agreement; Retention Policy Superseded. This Agreement contains the entire agreement of Executive and the Company with respect
to severance or termination pay. The payments and benefits provided hereunder shall be in lieu of any other payments or benefits
to which the Executive would otherwise be entitled under any other severance plan or program or arrangement sponsored by the Company
(including, without limitation, the Retention Policy), and Executive’s rights under all such plans, programs, arrangements
and agreements shall be superseded and terminated as of the Effective Date. This Agreement shall constitute an “employment
agreement” for purposes of the Company’s Retention Policy for Officers (or any successor thereto).

 

(c)          Successors.

 

(i)          The
Company shall require any successor (whether direct or indirect and whether by purchase, lease, merger, consolidation, liquidation
or otherwise) to all or substantially all of the business and/or assets of the Company to expressly assume and agree to perform
this Agreement in the same manner and to the same extent as the Company would be required to perform it in the absence of a succession.
Unless expressly provided otherwise, “Company” as used herein shall mean the Company as defined in this Agreement and
any successor to its business and/or assets as described above.

 

(ii)         This
Agreement and all rights of Executive hereunder shall inure to the benefit of, and be enforceable by, Executive’s personal
or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.

 

(d)          Taxes.
All payments and benefits made pursuant to this Agreement (including all reimbursements for Health Insurance Costs and Life Insurance
Costs, to the extent such reimbursements are treated as taxable wages) will be reported as taxable wages on a Form W-2 and will
be subject to deduction of all required federal, state, local and foreign withholding taxes and any other employment taxes the
Company may be required to collect or withhold.

 

    	6

    	 

    

 

(e)          No
Assignment. Executive’s rights hereunder may not be anticipated, assigned, attached, garnished, optioned, transferred
or made subject to any creditor’s process, whether voluntarily, involuntarily or by operation of law, except by will or the
laws of descent and distribution. Any action in violation of this Section 9(e) shall be void.

 

(f)          Internal
Revenue Code Section 409A.

 

(i)          This
Agreement is intended to comply with the requirements of section 409A of the Internal Revenue Code of 1986, as amended (“Section
409A”). Should there arise any ambiguity as to whether any provision of this Agreement contravenes one or more applicable
requirements or limitations of Section 409A and the Treasury Regulations thereunder, such provision shall be interpreted, administered
and applied in a manner that complies with the applicable requirements of Section 409A and the Treasury Regulations thereunder.

 

(ii)         Notwithstanding
any provision in this Agreement the contrary, no payment or benefit under this Agreement that constitutes an item of deferred compensation
under Section 409A and becomes payable by reason of a Qualifying Termination or a Change of Control Termination will be made
to Executive until Executive incurs a “separation from service,” within the meaning of Section 409A and the Treasury
Regulations thereunder. For purposes of this Agreement, each amount to be paid or benefit to be provided to Executive shall be
treated as a separate identified payment or benefit for purposes of Section 409A. In addition, no payment or benefit that constitutes
an item of deferred compensation under Section 409A and becomes payable by reason of Executive’s separation from service
will be made to Executive prior to the earlier of (i) the first day of the seventh month following the date of such separation
from service or (ii) the date of Executive’s death, if Executive is deemed at the time of such separation from service to
be a specified employee (as determined in accordance with Section 409A and the Treasury Regulations thereunder) and such delayed
commencement is otherwise required in order to avoid a prohibited distribution under Section 409A. Upon the expiration of
the applicable deferral period, all payments and benefits deferred pursuant to this paragraph (whether they would have otherwise
been payable in a single sum or in installments in the absence of such deferral) shall be paid or provided to Executive in a lump
sum on the first day of the seventh month after the date of Executive’s separation from service or, if earlier, the first
day of the month immediately following the date the Company receives proof of Executive’s death. Any remaining payments or
benefits due under this Agreement will be paid in accordance with the normal payment dates specified herein.

 

(iii)        Any
reimbursements or other in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements
of Section 409A, including, where applicable, the requirement that (1) all such reimbursements will be made on or before the last
day of the your taxable year following the taxable year in which Executive incurred such reimbursed expense, (2) the right to reimbursement
or in-kind benefits will not be subject to liquidation or exchange for another benefit, (3) the amount of expenses eligible for
reimbursement, or the in-kind benefits provided, during any taxable year of Executive will not affect the expenses eligible for
reimbursement, or the in-kind benefits to be provided, in any other taxable year of Executive, and (4) any reimbursement will be
for expenses incurred only during the period of time specified in this Agreement.

 

    	7

    	 

    

 

(g)          Amendments.
The Company may, at any time and for any reason, amend or eliminate, in whole or in part, any or all of the payments and benefits
to be provided to Executive under Section 3 upon the occurrence of a Change of Control Termination; provided, however, that
any such amendment shall become effective twelve (12) months following the date such amendment is approved by the Board, and no
such amendment shall become effective following a Change of Control Termination. Except as set forth in this Section 9(g), this
Agreement may not be amended or modified except by an instrument in writing executed by, or on behalf of, Executive and the Company.

 

(h)          Counterparts.
This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which shall constitute
the same instrument. Facsimile or other electronic copies of such signed counterparts may be used in lieu of the originals for
any purpose.

 

(i)          Choice
of Law. The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State
of New Jersey without regard to the conflicts of laws principles thereof.

 

    	8

    	 

    

 

IN WITNESS WHEREOF, each of the parties
has executed this Retention Agreement, in the case of the Company by its duly authorized officer, as of the day and year first
above written.

 

	 	EXECUTIVE:
	 	 
	 	/s/ Leslie J. Browne, Ph.D.
	 	Leslie J. Browne, Ph.D.
	 	 
	 	Senesco Technologies, Inc.:
	 	 
	 	/s/ Joel Brooks
	 	By: Joel Brooks
	 	Its: Chief Financial OfficerExhibit 10

Exhibit 10.1

AMENDMENT AND WAIVER AGREEMENT

THIS AMENDMENT AND WAIVER AGREEMENT (this “Agreement”), dated as of _____, 2014, is made and entered into by and among Vycor Medical, Inc., a Delaware corporation (the “Company”) and the signatories (the “Purchasers”) to that certain Securities Purchase Agreement, dated as of [DATE OF EACH AGREEMENT] (the “Purchase Agreement”), by and among the Company and the Purchasers.  Any defined term used herein but not otherwise defined shall have the meaning ascribed to such term in the Purchase Agreement.  

WHEREAS, pursuant to the Purchase Agreement, the Purchasers purchased [NUMBER OF SHARES] shares of Common Stock (the “Shares”), Series A Warrants to purchase up to [NUMBER OF WARRANT SHARES] shares of Common Stock (the “Series A Warrants”) and Series B Warrants to purchase up to [NUMBER OF SHARES] share of Common Stock (the “Series B Warrants,” together with the Series A Warrants, the “Warrants” and the Warrants together with the Shares, the “Securities”);  

WHEREAS, the Purchase Agreement, which is a series of purchase agreements, was entered into in connection with the Company’s offering of up to $5 million, in the aggregate, of shares of Common Stock and Common Stock purchase warrants (the “Offering” and such shares of Common Stock, the “Offering Shares”)

WHEREAS, Section 4.15 of the Purchase Agreement provides for per share price protection for the Shares upon any Dilutive Issuance (the “Per Share Price Protection Provision”) in connection with a Subsequent Equity Sale and Section 3(b) of the Series A Warrants provides for anti-dilution protection upon any Dilutive Issuance in connection with a Subsequent Equity Sale (the “Anti-Dilution Provision”); 

WHEREAS, the Company wishes to 

delete in their entirety the Per Share Price Protection Provision and the Anti-Dilution Provision; 

WHEREAS, Section 4.12(a) of the Purchase Agreement provides that the Company not issue any shares of Common Stock or Common Stock Equivalents until 60 days after the Effective Date; 

WHEREAS, pursuant to the Purchase Agreement, the Company and the Purchasers entered into the Registration Rights Agreement, dated as of [INSERT DATE] (the “Registration Rights Agreement”), pursuant to which the Company is required to register the Securities and shall not be permitted to file another registration statement until such time that the registration statement registering the Securities (the “Registration Statement”) is declared effective by the Commission; and

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Company and the Purchasers agree as follows:

1.

Amendments.

a.

Amendments to Purchase Agreement.  The Company and the Purchasers hereby agree to delete the Per Share Price Protection Provision and replace it with a covenant by the Company that it will not issue for cash shares of Common Stock or Common Stock Equivalents below an effective per share price of $2.05 (subject to adjustment for forward and reverse stock splits and the like that occur after the date hereof).  As such, Section 4.15 of the Purchase Agreement is amended and restated in its entirety as follows:

“Restriction on Dilutive Issuances.  From the date hereof until 12 months from the Effective Date, neither the Company nor any Subsidiary shall issue, enter into any agreement to issue or announce the issuance or proposed issuance for cash of any shares of Common Stock or Common Stock Equivalents with an effective per share price below $2.05 (subject to adjustment for forward and reverse stock splits and the like that occur after the date hereof).”

b.

Amendment to Series A Warrants.  The Company and the Purchasers hereby agree to delete the Anti-Dilution Provision and replace it with a covenant by the Company that it will not issue for cash shares of Common Stock or Common Stock Equivalents below an effective per share price of $2.05 (subject to adjustment for forward and reverse stock splits and the like that occur after the date hereof).  As such, Section 3(b) of the Series A Warrants is amended and restated in its entirety as follows:

“Restriction on Dilutive Issuances.  From Initial Exercise Date until 12 months from the Effective Date, neither the Company nor any Subsidiary shall issue, enter into any agreement to issue or announce the issuance or proposed issuance for cash of any shares of Common Stock or Common Stock Equivalents with an effective per share price below $2.05 (subject to adjustment for forward and reverse stock splits and the like that occur after the Initial Exercise Date).”

c.

Amendment to Registration Rights Agreement.  The Company and the Purchasers hereby agree to include the New Securities on the Registration Statement.  As such, the first sentence of Section 6(b) of the Registration Rights Agreement is hereby amended and restated in its entirety as follows:

“Except in connection with (i) transactions contemplated by clause (d) under Exempt Issuance and (ii) the issuance and sale of any securities of the Company, provided that any such sale is consummated on or before the Filing Date and that the effective per share price is equal to at least $2.05 (subject to adjustment for forward and reverse stock splits and the like that occur after the date hereof), neither the Company nor any of its security holders (other than the Holders in such capacity pursuant hereto) may include securities of the Company in any Registration Statements other than the Registrable Securities.”

d.

Amendment to Subsequent Equity Sales.  The Company and the Purchasers hereby agree to delete Section 4.12(a) in its entirety.  As such, Section 4.12(a) is amended and restated in its entirety as follows:

“From the date hereof until 60 days after the Effective Date, neither the Company nor any Subsidiary shall issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents with gross cash proceeds of greater than $1.5 million.”  

2.

Required Minimum Approval.  Notwithstanding Section 5.5 of the Purchase Agreement, the amendments and waivers pursuant to this Agreement will only take effect upon execution of this Agreement by (i) Purchasers holding at least 80% in interest of the Shares outstanding (the “Required Minimum Approval”) and (ii) purchasers holding at least 80% in interest of the Offering Shares; provided, however, the amendment to the Series A Warrants pursuant to Section 1(b) of this Agreement shall only take effect to those Purchasers who have entered into this Agreement.  In the event that the Company does not obtain the Required Minimum Approval, the amendments and waivers pursuant to this Agreement will be null and void and all provisions of the Transaction Documents will remain in full force and effect.   

 

3.

Additional Company Representations.  The Company’s execution and delivery of this Agreement and the Company’s consummation of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, its board of directors or the Company’s stockholders in connection therewith.  This Agreement has been duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms.

4.

Fees and Expenses.  Except as set forth in this section, each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement.

5.

Transaction Documents.  The Purchase Agreement and the related Transaction Documents are hereby amended so that the term “Transaction Documents” includes this Agreement.  The foregoing amendments are given solely in respect of the transactions contemplated hereby.  Except as expressly set forth above, all of the terms and conditions of the Transaction Documents shall continue in full force and effect after the execution of this agreement and shall not be in any way changed, modified or superseded by the terms set forth herein.

6.

Public Disclosure.  On or before 8:30 a.m. (New York City time) on the second Trading Day immediately following the date hereof, the Company shall file a Current Report on Form 8-K, reasonably acceptable to the Holders disclosing the material terms of the 

transactions contemplated hereby. The Company shall consult with the Purchasers in issuing any other press releases with respect to the transactions contemplated hereby.

7.

Governing Law.  All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed by the terms of the Purchase Agreement.

8.

Execution and Counterparts. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party, and such counterparts may be delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

			
	 
	VYCOR MEDICAL, INC.

	 
	 
	 

	 
	 
	 

	 
	By:

	 

	 
	 
	Name:

	 
	 
	Title:

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

SIGNATURE PAGE FOR PURCHASERS FOLLOW]

[HOLDER'S SIGNATURE PAGE TO VYCO AMENDMENT AGREEMENT]

IN WITNESS WHEREOF, the undersigned have caused this Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

Name of Purchaser: __________________________

Signature of Authorized Signatory of Purchaser: __________________________

Name of Authorized Signatory: _________________________

Title of Authorized Signatory: __________________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}]]